DBP International AB: positive response for SI-053 from Ethical Committee in the Netherlands has been received
Double Bond Pharmaceutical International AB (publ) ("DBP") takes the final step towards the start of clinical trial phase 1 in the Netherlands of its front-line product SI-053 in patients with glioblastoma – positive response from Ethical Committee of the Netherlands (Medisch Ethische Toetsings Commissie) has been received. "We are very pleased to have succeeded in reaching this important milestone in the development of SI-053 to satisfy the unmet medical needs of patients suffering from Glioblastoma." - comments Igor Lokot, CEO of DBP. “We are now very enthusiastic to find the most